Meropenem/vaborbactam activity against carbapenem-resistant Klebsiella pneumoniae from catheter-related bloodstream infections
Frontiers in Cellular and Infection Microbiology · 2025
DOI: 10.3389/fcimb.2025.1616353 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Francesca Sivori und 10 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology and Virology, San Gallicano Dermatological Institute IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Catheter-Related Infections, Klebsiella pneumoniae, Klebsiella Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Carbapenem-resistant Klebsiella pneumoniae (CRKP) poses a significant threat in oncology settings due to its multidrug resistance and ability to form biofilms on indwelling medical devices.
Methods
This study investigated the in vitro and in vivo activity of meropenem/vaborbactam (MEV) against two CRKP isolates recovered from catheter-related bloodstream infections in patients undergoing orthopedic oncologic surgery.
Results
Whole-genome sequencing identified the isolates as ST101 and ST307, harboring resistance determinants including bla KPC-3 and bla OXA-1 , distributed across IncFII and IncFIB plasmid replicons. Both isolates exhibited extensive resistance to β-lactams, aminoglycosides, and fluoroquinolones but remained susceptible to MEV. Phenotypic assays revealed enhanced biofilm formation and metabolic activity compared to the reference strain Kp ATCC 13883 in the absence of hypervirulence-associated genes. MEV demonstrated bactericidal activity against both planktonic and biofilm-associated cells, with minimum bactericidal concentration (MBC 90 ) and minimum biofilm eradication concentration (MBEC 90 ) values of 0.5/8 μg/ml for CRKP ST101, 0.12/8 μg/ml for CRKP ST307, and 0.25/8 μg/ml for the Kp ATCC 13883 strain. In the Galleria mellonella infection model, MEV significantly improved larval survival following the CRKP challenge.
Discussion
These findings demonstrate that MEV exhibits activity against planktonic and biofilm-associated CRKP cells and highlight the need for further investigation in managing catheter-related bloodstream infections caused by multidrug-resistant K. pneumoniae .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Microbiology and Virology, San Gallicano Dermatological Institute IRCCS, Rome, Italy.
- Hospital Infection Control Committee, Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy.
- Department of Biology and Biotechnology "C. Darwin", Sapienza University of Rome, Rome, Italy.
Zitieren
APA
Sivori, F., Francalancia, M., Truglio, M., Cavallo, I., Pronesti, C., Fabrizio, G., Celesti, I., Cazzani, A., Furzi, L., Pimpinelli, F., & Di Domenico, E. G. (2025). Meropenem/vaborbactam activity against carbapenem-resistant Klebsiella pneumoniae from catheter-related bloodstream infections. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1616353
Vancouver
Sivori F, Francalancia M, Truglio M, Cavallo I, Pronesti C, Fabrizio G, et al. Meropenem/vaborbactam activity against carbapenem-resistant Klebsiella pneumoniae from catheter-related bloodstream infections. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1616353
BibTeX
@article{Sivori2025,
author = {Sivori, Francesca and Francalancia, Massimo and Truglio, Mauro and Cavallo, Ilaria and Pronesti, Carmelina and Fabrizio, Giorgia and Celesti, Ilaria and Cazzani, Andrea and Furzi, Lorenzo and Pimpinelli, Fulvia and Di Domenico, Enea Gino},
title = {Meropenem/vaborbactam activity against carbapenem-resistant Klebsiella pneumoniae from catheter-related bloodstream infections},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
doi = {10.3389/fcimb.2025.1616353}
}
EUVIMED